Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1542/peds.2024-069114MC | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Cost-effectiveness of budesonide-formoterol in maintenance therapy of asthma patients.
Rev Alerg Mex
December 2024
Master's in economics, HS Pharmacoeconomic Research, Mexico City, Mexico.
Article Synopsis
- The study aimed to analyze the cost-effectiveness of budesonide/formoterol compared to other asthma treatments at Mexico's National Institute for Respiratory Diseases.
- Budesonide/formoterol had a lower average cost per patient ($733.36 USD) compared to fluticasone/vilanterol ($767.24 USD), and it showed a significant reduction in exacerbations with an incremental cost-effectiveness ratio (ICER) of $613.31 USD for better management.
- Overall, budesonide/formoterol was found to be a very cost-effective treatment option, suggesting it could reduce healthcare costs associated with emergency visits and hospitalizations despite fewer exacerbations per patient.
Reducing ethnic inequities: Patterns of asthma medication use and hospital discharges in Māori in Aotearoa New Zealand.
Respirology
December 2024
Medical Research Institute of New Zealand, Wellington, New Zealand.
Background And Objective: In Aotearoa New Zealand (NZ) widespread transition to budesonide/formoterol maintenance and/or reliever regimens in clinical practice is temporally associated with reduced rates of asthma hospitalization. It is unknown whether this association is observed in Māori, the indigenous population of NZ, who experience a disproportionate burden from asthma. We investigated patterns in asthma medication use and hospital admissions in Māori in NZ.
View Article and Find Full Text PDFBe SMART About Asthma Management: Single Maintenance and Reliever Therapy.
J Am Board Fam Med
October 2024
From the University of Illinois Chicago College of Pharmacy, Department of Pharmacy Practice, Chicago, Illinois (AFI); University of Illinois College of Medicine at Chicago, Chicago, Illinois (CW); University of Illinois College of Medicine at Chicago, Chicago, Illinois (JL); University of Illinois College of Medicine at Chicago, Chicago, Illinois (KH); University of Illinois Chicago College of Pharmacy, Department of Pharmacy Practice, Chicago, Illinois (JBJ); University of Illinois Chicago College of Pharmacy, Department of Pharmacy Practice, Chicago, Illinois (ATE).
Single maintenance and reliever therapy (SMART) is an asthma treatment approach that utilizes combined inhaled corticosteroids and long-acting β-agonists for maintenance and quick relief therapy. Despite the evidence for its benefits in asthma treatment and its adoption into American and international asthma guidelines and recommendations, SMART remains a practice of some debate. This article reviews the available evidence for SMART and offers guidance for its integration into comprehensive asthma management.
View Article and Find Full Text PDFSingle inhaler combination inhaled corticosteroid-formoterol as both maintenance and reliever (SMART) compared with a step up of treatment with fixed-dose inhaled corticosteroid-long-acting β2-agonist maintenance with a short-acting β2-agonist as reliever in adolescents and adults with poorly controlled asthma in Colombia: a cost-utility analysis.
J Asthma
October 2024
Department of Pediatric Pulmonology, School of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile.
Objective: The aim of the present study was to determine the cost-utility of single inhaler combination inhaled corticosteroid and a long-acting β2-agonist (ICS/LABAs) as both maintenance and reliever (SMART) compared with a step-up maintenance treatment with a fixed medium to high dose of ICS combined with LABA and a short-acting β2-agonist (SABA) as reliever (ICS-LABA maintenance plus SABA) among patients aged 12 years or more with poorly controlled asthma in Colombia.
Methods: A Markov-type model was developed to estimate the costs and health outcomes of a simulated cohort of patients aged 12 years or more with uncontrolled asthma treated for 12 months. The main effectiveness data were obtained from a recent meta-analysis.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!